LEGN Relative Valuation
LEGN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, LEGN is overvalued; if below, it's undervalued.
Historical Valuation
Legend Biotech Corp (LEGN) is now in the Fair zone, suggesting that its current forward PS ratio of 30.29 is considered Fairly compared with the five-year average of -19.32. The fair price of Legend Biotech Corp (LEGN) is between 16.28 to 49.62 according to relative valuation methord.
Relative Value
Fair Zone
16.28-49.62
Current Price：29.72
Fair
381.97
PE
1Y
3Y
5Y
Trailing
Forward
34.03
EV/EBITDA
Legend Biotech Corp. (LEGN) has a current EV/EBITDA of 34.03. The 5-year average EV/EBITDA is -19.88. The thresholds are as follows: Strongly Undervalued below -74.38, Undervalued between -74.38 and -47.13, Fairly Valued between 7.36 and -47.13, Overvalued between 7.36 and 34.61, and Strongly Overvalued above 34.61. The current Forward EV/EBITDA of 34.03 falls within the Overvalued range.
213.08
EV/EBIT
Legend Biotech Corp. (LEGN) has a current EV/EBIT of 213.08. The 5-year average EV/EBIT is -13.38. The thresholds are as follows: Strongly Undervalued below -120.23, Undervalued between -120.23 and -66.81, Fairly Valued between 40.05 and -66.81, Overvalued between 40.05 and 93.48, and Strongly Overvalued above 93.48. The current Forward EV/EBIT of 213.08 falls within the Strongly Overvalued range.
30.29
PS
Legend Biotech Corp. (LEGN) has a current PS of 30.29. The 5-year average PS is 29.36. The thresholds are as follows: Strongly Undervalued below -13.12, Undervalued between -13.12 and 8.12, Fairly Valued between 50.60 and 8.12, Overvalued between 50.60 and 71.84, and Strongly Overvalued above 71.84. The current Forward PS of 30.29 falls within the Historic Trend Line -Fairly Valued range.
63.06
P/OCF
Legend Biotech Corp. (LEGN) has a current P/OCF of 63.06. The 5-year average P/OCF is -30.99. The thresholds are as follows: Strongly Undervalued below -104.71, Undervalued between -104.71 and -67.85, Fairly Valued between 5.87 and -67.85, Overvalued between 5.87 and 42.73, and Strongly Overvalued above 42.73. The current Forward P/OCF of 63.06 falls within the Strongly Overvalued range.
21.74
P/FCF
Legend Biotech Corp. (LEGN) has a current P/FCF of 21.74. The 5-year average P/FCF is 29.26. The thresholds are as follows: Strongly Undervalued below -393.55, Undervalued between -393.55 and -182.14, Fairly Valued between 240.66 and -182.14, Overvalued between 240.66 and 452.07, and Strongly Overvalued above 452.07. The current Forward P/FCF of 21.74 falls within the Historic Trend Line -Fairly Valued range.
Legend Biotech Corp (LEGN) has a current Price-to-Book (P/B) ratio of 5.53. Compared to its 3-year average P/B ratio of 8.15 , the current P/B ratio is approximately -32.13% higher. Relative to its 5-year average P/B ratio of 10.83, the current P/B ratio is about -48.94% higher. Legend Biotech Corp (LEGN) has a Forward Free Cash Flow (FCF) yield of approximately -3.37%. Compared to its 3-year average FCF yield of -3.03%, the current FCF yield is approximately 11.21% lower. Relative to its 5-year average FCF yield of -3.68% , the current FCF yield is about -8.33% lower.
5.53
P/B
Median3y
8.15
Median5y
10.83
-3.37
FCF Yield
Median3y
-3.03
Median5y
-3.68
Competitors Valuation Multiple
The average P/S ratio for LEGN's competitors is 43.91, providing a benchmark for relative valuation. Legend Biotech Corp Corp (LEGN) exhibits a P/S ratio of 30.29, which is -31.01% above the industry average. Given its robust revenue growth of 69.99%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of LEGN decreased by 29.36% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 160.21M to 272.33M.
The secondary factor is the P/E Change, contributed -17.97%to the performance.
Overall, the performance of LEGN in the past 1 year is driven by Revenue Growth. Which is more sustainable.
People Also Watch
FAQ
Is Legend Biotech Corp (LEGN) currently overvalued or undervalued?
What is Legend Biotech Corp (LEGN) fair value?
How does LEGN's valuation metrics compare to the industry average?
What is the current P/B ratio for Legend Biotech Corp (LEGN) as of Nov 19 2025?
What is the current FCF Yield for Legend Biotech Corp (LEGN) as of Nov 19 2025?
What is the current Forward P/E ratio for Legend Biotech Corp (LEGN) as of Nov 19 2025?